Frontotemporal Dementia
114
24
36
53
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
11 trials with published results (10%)
Research Maturity
53 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.8%
2 terminated out of 114 trials
96.4%
+9.9% vs benchmark
5%
6 trials in Phase 3/4
21%
11 of 53 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 53 completed trials
Clinical Trials (114)
MSC-Exosome Therapy for Frontotemporal Dementia
Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
A Study of Caregiver Connections Via Technology in Dementia
GENetic Fronto Temporal Dementia Initiative in Lille
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
Eye Gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases: Links With Neuropsychiatric Disorders (EYE-ToM Study)
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Retinal Hyperspectral Imaging in Neurodegenerative Diseases
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Epidemiological Study in FRONtoTemporal Dementia
Neurological Soft Signs in Neurodegenerative Dementias
Phenotype, Genotype and Biomarkers 2
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Retinal Imaging in Neurodegenerative Disease
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes